SCM
INSY

Stevens Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Stevens Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-12,467
Closed -$147K – 1203
2016
Q3 		$147K Buy
+12,467
New +$190K 0.01% 827
2015
Q4 		– Sell
-8,570
Closed -$244K – 1251
2015
Q3 		$244K Buy
+8,570
New +$315K 0.01% 772

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stevens Capital Management's INSY Position: Q4 2016 in Review

Stevens Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2016, closing a stake of 12,467 shares — an estimated $147K sold.

Stevens Capital Management first reported a position in INSY in Q3 2015 and held it in 2 quarters. The position peaked at $244K in Q3 2015. 138 funds tracked by Wall St. Rank hold INSY as of Q4 2016.

  • Stevens Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Stevens Capital Management sold 12,467 Insys Therapeutics, Inc. shares in Q4 2016, an estimated $147K.
  • Stevens Capital Management first reported a position in Insys Therapeutics, Inc. in Q3 2015 and held it in 2 quarters.
  • Stevens Capital Management's Insys Therapeutics, Inc. position peaked at $244K in Q3 2015.
  • 138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2016.

Based on Stevens Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.